NovaBone to Introduce Revolutionary Bioactive Wedge at AOFAS 2025 Meeting

NovaBone Set to Showcase its Groundbreaking Bioactive Wedge at AOFAS 2025

At the upcoming American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia, NovaBone will unveil its cutting-edge Bioactive Pre-contoured Wedge (BPW). This revolutionary product represents a significant achievement in synthetic bone graft technologies, specifically focused on enhancing orthopedic surgeries.

A New Era in Bone Grafting

What sets the Bioactive Pre-contoured Wedge apart is its composition as the first fully synthetic, porous bioactive glass solution available on the market. Designed with osteostimulation at its core, the BPW is classified as a non-metal device that prioritizes both patient safety and operational efficiency in surgical settings. It is adept at correcting bone deformities and filling osseous defects, while simultaneously offering a fully resorbable scaffold that accelerates natural bone regeneration.

Scott Day, Vice President of Marketing & Business Development at NovaBone, stated, "The introduction of our Bioactive Pre-contoured Wedge offers an innovative solution tailored for orthopedic and podiatric surgeons. With our expertise in BioGlass manufacturing, we provide a viable alternative to traditional metal implants. Built in the USA, the wedges also boast a remarkable five-year shelf life, aiding in easier inventory management and reducing dependence on global supply chains."

Insights from Experts

Dr. Charles Cook, Clinical Assistant Professor of Orthopedic Surgery at The University of North Texas Health Science Center, has conducted studies on the BPW. He asserts that its pre-contoured design enhances surgical workflows and establishes a strong scaffold for bone growth, ensuring site stability and reducing the likelihood of graft failure. "Having this product as part of our surgical toolkit is essential for us,"
he commented.

Key Benefits of the Bioactive Pre-contoured Wedge

1. First to Market: The BPW is the first bioactive pre-contoured wedge and is regulated as a Class II medical device.
2. Bioactive Glass: Its bioactive glass structure ensures both osteoconductivity and osteostimulation, promoting healthy bone formation.
3. Fully Resorbable: Once implanted, the wedge is entirely replaced by native bone, eliminating the need for further surgical interventions for removal.
4. Cost-effective: This innovative product offers a more affordable solution compared to metal implants, along with a five-year shelf life.
5. Compatibility: The BPW seamlessly integrates with reconstructive plating and staple solutions, making it ideal for various surgical scenarios.

Hands-on Experience at AOFAS

Visitors to Booth #544 at the AOFAS 2025 Meeting will have a unique opportunity to engage with the Bioactive Pre-contoured Wedge through hands-on models, allowing them to observe its handling and anatomical fit. The NovaBone team will also facilitate discussions centered around scientific insights regarding the product’s design and efficacy.

With an impressive 20-year history, during which over two million devices have been implanted globally, NovaBone continually strives to lead the way in patient healing. Their commitment to innovation and science, coupled with a focus on surgeon-centric design, positions them at the forefront of the orthopedic industry.

About NovaBone

Founded on extensive research in bioactive glass science, NovaBone Products, LLC stands as a leader in synthetic bone graft technologies. Their portfolio of bioactive solutions not only supports bone regeneration but also promotes healing and repair, actively aiding the body’s natural healing mechanisms by attracting bone-forming cells. Trusted by professionals in orthopedic, neurosurgical, and dental fields, NovaBone delivers reliable and effective solutions for bone regeneration. To learn more, please visit www.novabone.com.